Daniel R. Greenberg

Dr. Daniel R. Greenberg

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in World Neurosurgery
Verified
Journal Article
Closed access
HBHriday P. Bhambhvani
Hriday P. Bhambhvani
DGDaniel R. Greenberg
Daniel R. Greenberg
SSSandy Srinivas
Sandy Srinivas
MGMelanie Hayden Gephart
Melanie Hayden Gephart

19 June 2019 in Neuromodulation: Technology at the Neural Interface
Verified
Journal Article
Closed access
PDF file
DGDaniel R. Greenberg
Daniel R. Greenberg
RSRaveen Syan
Raveen Syan
NYNichole Young-Lin
Nichole Young-Lin
CCCraig V. Comiter
Craig V. Comiter
EEEkene Enemchukwu
Ekene Enemchukwu

1 October 2020 in Urology
Verified
Journal Article
Closed access
DGDaniel R. Greenberg
Daniel R. Greenberg
ESEricka M. Sohlberg
Ericka M. Sohlberg
CZChiyuan A. Zhang
Chiyuan A. Zhang
VSVeronica E. Santini
Veronica E. Santini
CCCraig V. Comiter
Craig V. Comiter
EEEkene Enemchukwu
Ekene Enemchukwu

8 August 2019 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
DGDaniel R. Greenberg
Daniel R. Greenberg
YKYash S. Khandwala
Yash S. Khandwala
BBBenjamin N. Breyer
Benjamin N. Breyer
RMRoger Minkow
Roger Minkow
MEMichael L. Eisenberg
Michael L. Eisenberg
Introduction: Bicycle seat pressure on the perineum may impair arousal and clitoral erection, likely contributing to genital pain and numbness experienced by female cyclists. Aim: We aimed to identify the association between genital pain and numbness experienced by female cyclists and female sexual dysfunction (FSD). Methods: Female cyclists were recruited to complete an online survey using the Female Sexual Function Index (FSFI), a validated questionnaire to assess FSD. Cyclist demographics, experience, preferred riding style, use of ergonomic cycle modifications, and genital discomfort while riding were also queried. Multivariate logistic regression analysis was used to evaluate risk factors of FSD. Main Outcome Measures: The main outcome was FSFI score, which is used to diagnose FSD when the FSFI score is <26.55. Results: Of the survey respondents, 178 (53.1%) completed the survey and FSFI questionnaire. Mean age was 48.1 years (±0.8 standard error [SE]), and the average riding experience was 17.1 years (±0.9 SE). Overall, 53.9% of female cyclists had FSD, 58.1% reported genital numbness, and 69.1% reported genital pain. After adjusting for age, body mass index, relationship status, smoking history, comorbidities, and average time spent cycling per week, females who reported experiencing genital numbness half the time or more were more likely to have FSD (adjusted odds ratio [aOR], 6.0; 95% CI, 1.5–23.6; P = .01), especially if localized to the clitoris (aOR, 2.5; 95% CI, 1.2–5.5; P = .02). Females that reported genital pain half the time or more while cycling also were more likely to have FSD (aOR, 3.6; 95% CI, 1.2–11.1; P = .02). Cyclists experiencing genital pain within the first hour of their ride were more likely to have FSD (aOR, 12.6; 95% CI, 2.5–63.1; P = .002). Frequency and duration of cycling were not associated with FSD. Analysis of FSFI domains found that the frequency of numbness was correlated with decreased arousal, orgasm, and satisfaction during intercourse, whereas the frequency of pain significantly reduced arousal, orgasm, and genital lubrication. Clinical Implications: Female cyclists that experience numbness and/or pain have higher odds of reporting FSD. Strengths & Limitations: Our study includes a validated questionnaire to assess FSD and queries specific characteristics and symptoms of genital pain and genital numbness; however, the study is limited by its cross-sectional survey design. Conclusion: This study highlights the need for cyclists to address genital pain and numbness experienced while cycling, and future studies are required to determine if alleviating these symptoms can reduce the impact of cycling on female sexual function.

1 March 2021 in Surgical Oncology
Verified
Journal Article
Closed access
HBHriday P. Bhambhvani
Hriday P. Bhambhvani
AZAlvaro Zamora
Alvaro Zamora
KVKyla Velaer
Kyla Velaer
DGDaniel R. Greenberg
Daniel R. Greenberg
KSKunj R. Sheth
Kunj R. Sheth

14 February 2019 in The Journal of Sexual Medicine
Verified
Journal Article
Closed access
DGDaniel R. Greenberg
Daniel R. Greenberg
MRMichael T. Richardson
Michael T. Richardson
JTJonathan D. Tijerina
Jonathan D. Tijerina
MBMichelle B. Bass
Michelle B. Bass
MEMichael L. Eisenberg
Michael L. Eisenberg
Introduction: Erectile dysfunction (ED) is a common medical condition that requires high-quality evidence to guide clinical practice; however, systematic reviews (SRs) and meta-analyses (MAs) often vary in quality, raising concerns regarding the validity of their results. Aim: To perform an objective analysis of SRs and MAs in ED treatment and management and to report on the quality of published literature. Methods: A comprehensive search in PubMed/MEDLINE and EMBASE of 12 high-impact urology journals was used to identify relevant publications. 2 authors independently performed searches, screened citations for eligibility, extracted data for analysis, and graded methodologic quality using A Measurement Tool to Assess Systematic Reviews (AMSTAR) criteria. Main Outcome Measures: The main outcome was AMSTAR score, which is a validated tool to evaluate the quality of SRs and MAs. Results: 31 publications met inclusion criteria and were included in the analysis. The mean AMSTAR score (± SD) among all publications was 6.5 (±2.2) of 11, reflecting “fair to good” quality. 74.2% of systematic reviews and meta-analyses focused on pharmaceutical therapy for ED, with 51.6% studying the effect of phosphodiesterase-5 inhibitors. Only 1 SR/MA studied intracavernosal injection therapy and vacuum erection devices. No publications studied intraurethral injection therapy or implantable penile prostheses. Although not statistically significant, there has been a trend of increasing quality of SRs/MAs over time (P = .072). Clinical Implication: The methodologic quality of SRs/MAs should be assessed to ensure high-quality evidence for clinical practice guidelines in ED treatment and management. Strength & Limitation: The data showed that methodologic quality of SRs/MAs in the treatment and management of ED is increasing over time. 12 high-impact urology journals were included in our search, which may introduce selection bias in our results. Conclusions: This review highlights a need for increased effort to study second- and third-line treatments for patients who fail oral therapy.